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Abstract 
Background: There is a need to ascertain the type and level of treatment burden experienced by people with co-
morbidities. This is important in order to identify the characteristics of participants who are at most risk of treatment 
burden.  
Objective: The aim of this study is to identify the characteristics of participants who are at most risk of treatment 
burden. 
Methods: This cross-sectional study was part of a larger project and recruitment was conducted across four Australian 
regions: rural, semi-rural and metropolitan. Participants were asked about their treatment burden using an adapted 
version of a measure, which included the following five dimensions: medication, time and administrative, lifestyle 
change, social life, and financial burden. 
Results: In total, 581 participants with various chronic health conditions reported a mean global treatment burden of 
56.5 out of 150 (SD = 34.5). Number of chronic conditions (β = .34, p < .01), age, (β = -.27, p < .01), the presence of 
an unpaid carer (β = .22, p < .001), and the presence of diabetes and other endocrine conditions (β = .13, p < .01) were 
significant predictors of overall treatment burden. For the five dimensions of treatment burden, social, medicine and 
administrative burden were predicted by the same cluster of variables: number of conditions, age, presence of an 
unpaid carer and diabetes. However, in addition to these variables, financial dimensions were also predicted by 
education level, ethnicity and health insurance. Educational level also influenced lifestyle burden.  
Conclusion: A substantial proportion of community-dwelling adults with chronic conditions have considerable levels 
of treatment burden. Specifically, health professionals should provide greater focus on managing overall treatment 
burden for persons who are of young age, have an endocrine condition or an unpaid carer, or a combination of these 
factors. 
 
Key Points for Decision Makers 
• Healthcare systems and professionals should mostly be aware of younger adults with multiple chronic when 
designing interventions to reduce treatment burden. 
• Although the social, medicine and administrative burden of burden are highly inter-related and could be addressed 
through the same changes in medical practice, further strategies are required for lifestyle and financial dimensions. 
1. Background 
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The challenge for health professionals has shifted from treating acute illness to helping people manage chronic 
conditions [1, 2]. Chronic conditions or illness, such as diabetes and cardiovascular disease, are now in epidemic 
proportions globally, but the impact or burden of treatment on patients remains poorly understood. The ‘work’ of 
living with a chronic condition, labelled as treatment burden, can be overwhelming for many people. This can involve 
using medications, visiting multiple health professionals, self-monitoring, having medical and laboratory tests, and 
lifestyle change, e.g. physical exercise [1, 3]. The concept of treatment burden can extend to learning about treatments 
and their consequences, engaging with and mobilising support networks and adhering to treatment changes. Tran et 
al., [4] in the taxonomy of treatment burden, indicated that healthcare which imposes a burden on patients includes: 
management of medications, organising and performing non-pharmacological treatment, lifestyle changes, condition 
and treatment follow-up, organising formal caregiver care, paperwork tasks, and learning and developing an 
understanding of illness and treatment. More recently, Demain et al., [5] drew attention to the sociological aspect of 
treatment burden, suggesting that burden is not only brought about by the workload associated with treatment, but 
also the impact of that workload on everyday activities and patient identity. 
Although the term treatment burden has been used interchangeably with the ‘burden of illness’, there is a 
fundamental difference between the two concepts. Treatment burden focuses on negative experiences resulting from 
the process of undertaking treatment, whereas the burden of illness refers to the impact of a chronic illness on a person 
[6]. Thus, treatment burden is a constructed concept that could be minimised by thoughtful intervention(s) within the 
healthcare system. 
Despite its overarching aim to improve health and wellbeing, the healthcare system actually contributes to 
treatment burden through poor coordination of healthcare services, unhelpful professional-patient relationships and 
inadequate information [7, 8]. Furthermore, there is evidence that health professionals lack the tools to identify those 
people who are overwhelmed by the ‘work’ of being a patient and implement strategies to ease this burden [9]. As 
noted by Eton et al. [8], in response to poor patient outcomes health professionals can intensify therapeutic treatment 
(e.g. increase medication use, the provision of additional services), resulting in more work for the patient and 
ultimately, greater treatment burden. Therapeutic interventions should assess treatment burden and adopt strategies to 
minimise the ‘work’ of being a patient, otherwise treatment burden can lead to treatment non-adherence, side effects 
or worsening or recurrence of symptoms, poor quality of life and ineffective use of finite health resources [10, 11]. 
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Most validated measures of treatment burden have been developed for specific chronic conditions, such as 
diabetes and asthma [12, 13]. Even within some of these studies, treatment burden has generally been included as one 
component within a multidimensional instrument, specifically designed to measure overall quality of life and 
treatment satisfaction [10]. Yet, chronic conditions rarely occur in isolation, with many people experiencing co-
morbidity of at least two or more conditions [14]. In Australia, 20% of the population experience multiple chronic 
conditions [15]. Not surprisingly, there is evidence that treatment burden increases with co-morbidity [1], suggesting 
that the experiences of people with multiple and more complex conditions may be different from those people with 
only one condition [10]. There is clearly a need to ascertain the type and level of treatment burden experienced by 
people with co-morbidities.  
The aim of this study was to identify the characteristics of participants who are at most risk of treatment burden. 
The findings will inform the way in which healthcare systems can target and respond to the needs of those people 
experiencing treatment burden. An understanding of the predictors of treatment burden will increase the ability of 
health professionals to identify whether patients are feeling overburdened by their treatment, thereby tailoring 
appropriate treatment strategies to meet their individual needs. 
 
2. Methods 
2.1.  Design and Recruitment 
This cross-sectional study was part of a larger project, which explored the experiences and expectations of people 
with chronic conditions and/or their carers of health professionals and health services. Ethical approval was obtained 
from a tertiary institution and from one state Government Health Department). To participate in the study, participants 
needed to have one or more chronic condition(s), or be an unpaid carer of someone with a chronic condition, or both 
(a carer who personally had a chronic condition). Recruitment was conducted across four Australian regions: Logan-
Beaudesert and Mount Isa/North West regions of Queensland, the Northern Rivers area of New South Wales and the 
greater Perth area of Western Australia. These regions reflected significant diversity in geography (e.g. metropolitan 
versus rural), accessibility, socioeconomic status and culture.  
Recruitment for the study involved an intensive campaign conducted through Non-Government consumer 
organisations (e.g. Diabetes Australia), community pharmacies and local area health services. Advertisements were 
placed in suburban and regional newspapers, promotional flyers were distributed in public places and email 
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distributions were sent through membership/client lists of key health and professional organisations and services. 
Recruitment occurred in places likely to be visited by people with chronic conditions, such as hospital clinics, cardiac 
rehabilitation units, and community pharmacies. Face-to-face recruitment was conducted at various shopping centres, 
malls and markets to access those who may not be regular health service users. To ensure diversity, Aboriginal and 
Torres Strait Islander peoples and those from culturally and linguistically diverse backgrounds were recruited from 
community groups and Non-Government organisations servicing these communities.  
 
2.2 Measures 
The survey incorporated measures of treatment burden, self-reported health status, health service utilisation, and 
socio-demographics. It also included a discrete choice experiment to elicit healthcare preferences, which has been 
reported elsewhere [16]. Further details on these measures are provided below. 
 
2.2.1 Treatment burden  
Participants were asked about their treatment burden using an adapted version of a measure developed and 
validated by Tran et al. [1] in France in 2012, called Treatment Burden Questionnaire© (TBQ). This measure was 
chosen as it was, at the time, the most comprehensive generic measure (i.e. not specific to a single condition) of 
treatment burden identified in the literature. Additionally, the TBQ© was rigorously developed and validated by Tran 
et al. [1]. For example, the authors conducted factor analysis, construct validity and the test-retest method to ensure 
appropriate psychometric development of the instrument. Tran et al. [4] subsequently validated the measure in an 
English speaking population in 2015, which was unavailable during the data collection stage of this study. In their 
most recent version, Tran et al included a question about relationships with healthcare providers and a question about 
financial burden. We had already included a question measuring financial burden and an additional question about 
side effects of treatment, which was not asked by Tran et al in [1]. The inclusion of financial burden and the subsequent 
validation of the original TBQ© measure in an English speaking, community based population strengthens the use of 
this tool in the present study.  
Initially, Tran et al. [1] developed a measure to assess treatment burden “associated with the following four 
categories: (i) taking medicines, (ii) self-surveillance, laboratory tests, doctor visits, need for organization and, 
administrative tasks, (iii) following advice on diet and physical exercise and (iv) social impact of the treatment” (p. 
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2). Recently, Tran et al. [4] found that the themes identified in their study complemented their treatment burden 
questionnaire they developed three years earlier.  
Tran et al. [17] suggested that new items could arise in different contexts, and the measure was adapted to suit 
the social and cultural context of Australia. For example, because of the financial circumstances of the French public 
health system (free healthcare for patients with chronic conditions), Tran et al. [1] did not measure the financial burden 
of treatment. Hence, we included the following item to measure the financial burden of treatment: the financial impact 
of your medication and treatment (e.g. paying for medication and healthcare professional fees, paying private health 
insurance premiums, losing your income, etc.). Furthermore, the original measure did not incorporate side-effects of 
treatment, particularly medication. However, our research and a review of the literature indicated that the side-effects 
of medication were a common burden for people. Hence, we included the item: the side-effects of your medication, 
treatment and medical tests.  
Other minor grammatical changes were made to the original measure to suit the Australian context. Overall, 
treatment burden was measured via 15 items in our survey (Table 1). Our adapted measure included the following five 
dimensions: medication burden (5 items on the burden associated with medicine use and its side effects), time and 
administrative burden (5 items on the burden associated with self-surveillance, doctor visits, need for organization, 
administrative tasks, etc.), lifestyle change burden (2 items on the burden associated with changing lifestyle, i.e., diet, 
exercise, sleep), social life burden (2 items on the burden associated with social life, i.e., family and relationships), 
and financial burden (1 item on the burden of costs of treatment and/or out of pocket expenses). For each item, 
participants were asked: when thinking about your treatment(s), how would you rate the following? (select one number 
only). Each item was measured using a scale of 0 to 10, (0 = no burden, 5 = some burden, 10 = considerable burden), 
with higher scores indicating higher levels of burden. In the current study, the Cronbach alpha coefficient for the 15 
item treatment burden measure was 0.93, indicating good levels of internal consistency. 
 
Table 1 
 
2.2.2 Self-reported health status 
Participants self-reported the number, type and duration of diagnosed chronic condition(s). Researchers clustered 
the responses into the following categories: diabetes and other endocrine conditions, cardiovascular conditions, mental 
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illness, musculoskeletal conditions, respiratory conditions and cancer. We also measured participants’ experiences of 
their chronic condition(s), and their frequency of medication and health and pharmacy services use. 
 
2.2.3 Socio-demographic characteristics 
A range of socio-demographic characteristics including age, gender, income, level of education, employment 
status, marital status, ethnic or cultural background, receipt of a government concession (i.e. increased or basic 
subsidies for healthcare costs), possession of private health insurance, and presence of an unpaid carer (i.e. a person 
who is not an employed carer, such as a family member) were collected.  
 
2.3 Procedure 
Data collection was mostly conducted by an independent Computer Assisted Telephone Internet (CATI) provider. 
The survey was first sent to an English language consultant with substantial experience working with health consumers 
to ensure that it was written in ‘plain English.’ The survey was then pilot tested by the CATI provider with a 
convenience sample of 36 participants (recruited from the personal contacts of all researchers) and minor amendments 
were made. Data collection was conducted between October 2013 and January 2014. The CATI provider sent surveys 
to participants for pre-reading approximately one to two weeks prior to conducting the survey. A CATI representative 
then contacted each participant via telephone to undertake the survey. Method and time of contact was based on each 
participant’s personal circumstances. For example, some participants were contacted via landline and others via cell 
(mobile) phone. A small number of interviews were conducted face-to-face by the research team (n = 54) to ensure 
inclusion of participants who were considered difficult to reach by telephone or who might have preferred face-to-
face discussion. This included Aboriginal and Torres Strait Islander peoples, culturally and linguistically diverse 
participants and younger employed men. Participants were offered a supermarket gift voucher (AU$50) as 
reimbursement for their time.  
 
2.4 Data analysis 
Analyses were conducted using SPSS Version 22.0 and Stata 13 software. Data were initially analysed 
descriptively. For each participant, the individual treatment burden item scores were summed to give a global score 
out of 150 indicating total treatment burden; higher scores represented a higher level of burden.  
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Stepwise multiple regression was used to test the ability of independent variables to predict overall levels of 
treatment burden (primary analysis) and treatment burden for each of the five dimensions (secondary analyses). The 
predictors were separated into two groups: (a) personal characteristics, and (b) disease characteristics. Groups of 
predictors were entered into the model simultaneously and then removed individually in a stepwise approach. The 
beta coefficients (β) were inspected to assess the unique contribution of each variable in predicting overall treatment 
burden. A β = .10 was considered to be a small effect, β = .30 was a medium effect, and β = .50 was a large effect 
(Cohen, 1988). 
 
Table 2 
 
There is only limited published data available in Australia about the demographic characteristic of individuals 
with chronic condition(s). We compared our sample to participants from the (Australian) National Health Survey 
2007-8 [18] that reported one or more chronic conditions (i.e. cardiovascular conditions, diabetes, cancer, asthma, 
arthritis, osteoarthritis and mental health conditions; Table 3). There were no significant differences in age, the 
proportion identifying as being from an Australian background, those reporting two or more conditions, or reporting 
a cardiovascular condition. However, females, those with a higher educational qualification, lower income or in receipt 
of government concession benefits, were over-represented in our sample whereas the employed and those with private 
health insurance were under-represented. Participants with diabetes and other endocrine, respiratory, or 
musculoskeletal conditions, cancer, or mental illness were over-represented in our sample.  
 
Table 3  
 
3. Results 
3.1 Sample characteristics  
Of 600 participants who consented to participate, 581 completed the surveys (Table 2). Participants had a mean 
age of 57.28 years (SD = 15.64) and the majority (n = 407; 70.0%) were female. Nearly one quarter (n = 139; 23.9%) 
experienced a chronic condition and also provided unpaid care for someone else. Although 59.7% (n = 359) of 
participants reported being from an Australian (non-indigenous) background, other participants were from diverse 
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cultural backgrounds, including Chinese, Filipino, Pacific Islander people, German, Italian, and New Zealanders. 
Furthermore, 8.7% (n = 52) of participants identified as being from an Aboriginal or Torres Strait Islander background. 
All participants had at least one chronic condition, but the majority (n = 501; 86.2%) reported having two or more 
chronic conditions. The most prevalent conditions were musculoskeletal conditions (e.g. arthritis, osteoporosis, 
chronic neck/back pain), cardiovascular conditions (e.g. heart disease, high blood pressure) and mental illness (e.g. 
anxiety, depression). 
 
3.2 Description of treatment burden 
Participants reported a mean global treatment burden of 56.5 (SD = 34.5) out of a possible score of 150 (where 
higher scores represent higher burden). When analysed individually for the five dimensions of treatment burden 
(highest possible score of 10), the highest levels of burden were reported in the financial (mean=5.4, SD = 3.6), 
lifestyle (mean=4.1, SD = 3.0), and social (mean = 4.0, SD = 3.1) dimensions, followed administrative (mean= 3.5, 
SD=2.4) and medicine (mean= 3.5, SD= 2.5). 
For treatment burden specifically, significant univariate positive relationships (Table 4) were found for the 
number of co-morbidities (.30, p < .01), mental illness (.25, p < .01), presence of an unpaid carer (.23, p < .01), 
diabetes-related conditions (.15, p < .01), and musculoskeletal conditions (.12, p < .01). The only significant negative 
relationship for treatment burden was with age (-.16, p < .01). Number of co-morbidities was found to have strong 
positive relationships with various types of chronic disease categories: mental illness (.51, p < .01), musculoskeletal 
conditions (.50, p < .01), respiratory conditions (.49, p < .01), cancer related conditions (.42, p < .01), and 
cardiovascular conditions (.40, p < .01). Number of co-morbidities showed a weaker relationship with diabetes-related 
conditions (.21, p < .01), compared to other disease categories. Age also showed significant relationships (in terms of 
size and statistically) with a number of variables, including income (-.27, p < .01), reaching the Pharmaceutical 
Benefits Scheme (PBS) Safety Net1 (.33, p < .01), number of co-morbidities (.27, p < .01), cardiovascular conditions 
(.46, p < .01), and musculoskeletal conditions (.28, p < .01). 
 
Table 4  
                                                          
1
 A government concession whereby the cost of prescription medicines for individuals and families is reduced once 
the PBS Safety Net threshold has been reached 
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3.3 Multivariate regression  
3.3.1 Total treatment burden  
Following stepwise multiple regression, the final model specification had statistically significant predictive 
capability (F(4, 558) = 38.78, p < .001). Twenty-one per cent of the variation in overall treatment burden was explained 
by the set of independent variables (R² = .22; adjusted R² = .21). Table 5 shows the raw and standardized regression 
coefficients of the predictors along with their correlations with treatment burden and their squared semi-partial 
correlations. The following four variables made significant (p < .001) contributions to the prediction of overall 
treatment burden: age, presence of an unpaid carer, number of chronic conditions, and the presence of diabetes and 
other endocrine conditions. 
Number of chronic conditions received the strongest weight in the model (standardised coefficient, β = .34, p < 
.01), followed by age, (β = -.27, p < .01), the presence of an unpaid carer (β = .22, p < .001), and the presence of 
diabetes and other endocrine conditions (β = .13, p < .01). The remaining variables did not have a significant impact 
(p ≤ 0.1) on the prediction of treatment burden: gender, being a carer or consumer, marital status, income, employment 
status, educational background, ethnic or cultural background, government concession, private health insurance, 
cardiovascular conditions, mental illness, musculoskeletal conditions, respiratory conditions, and cancer. 
 
Table 5 
 
The raw beta coefficients from the model suggest that the mean treatment burden for participants with one chronic 
condition other than an endocrine condition (including diabetes) and no unpaid carer was 62.8 (SE 5.0) out of a 
possible score of 150. The presence of an unpaid carer was associated with an increase in treatment burden of 17.6 
units, each additional chronic condition with an increase of 4.8 units, and the presence of an endocrine condition with 
a further 9.7 unit increase in treatment burden. Conversely, each additional year of age was associated with a reduction 
of 0.6 units in treatment burden. 
 
3.3.2 Treatment social burden 
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The final model specification (following stepwise multiple regression) had statistically significant predictive 
capability (F(4, 518) = 29.60, p < .001). Eighteen per cent of the variation in overall social burden was explained by 
the set of independent variables (R² = .19; adjusted R² = .18). Only the number of chronic conditions (standardised 
coefficient, β = .27, p < .001), the presence of an unpaid carer (β = .26, p < .001), age (β = -.21, p < .001), and the 
presence of diabetes and other endocrine conditions (β = .11, p < .001) were significant predictors.  
 
3.3.3 Treatment medicine burden 
The final model specification (following stepwise multiple regression) had statistically significant predictive 
capability (F(4, 517) = 26.14, p < .001). Sixteen per cent of the variation in overall medicine burden was explained 
by the following set of independent variables (R² = .17; adjusted R² = .16): number of chronic conditions (standardised 
coefficient, β = .32, p < .001), age (β = -.24, p < .001), the presence of an unpaid carer (β = .17, p < .001), and the 
presence of diabetes and other endocrine conditions (β = .09, p < .050).  
 
3.3.4 Treatment administrative burden 
The final model specification (following stepwise multiple regression) had statistically significant predictive 
capability (F(4, 516) = 24.77, p < .001). Sixteen per cent of the variation in overall administrative burden was 
explained by the following set of independent variables (R² = .16; adjusted R² = .16): number of chronic conditions 
(standardised coefficient, β = .25, p < .001), age (β = -.21, p < .001), the presence of an unpaid carer (β = .19, p < 
.001), and the presence of diabetes and other endocrine conditions (β = .18, p < .001).  
 
3.3.5 Treatment lifestyle burden 
The final model specification (following stepwise multiple regression) had statistically significant predictive 
capability (F(4, 518) = 18.80, p < .001). Fifteen per cent of the variation in overall lifestyle burden was explained by 
the set of following independent variables (R² = .16; adjusted R² = .15): number of chronic conditions (standardised 
coefficient, β = .30, p < .001), the presence of diabetes and other endocrine conditions (β = .18, p < .001), age (β = -
.15, p < .001), the presence of an unpaid carer (β = .10, p < .001), and educational background (β = .10, p < .05). 
 
3.3.6 Treatment financial burden 
Treatment burden and chronic illness 
 
13 
The final model specification (following stepwise multiple regression) had statistically significant predictive 
capability (F(7, 518) = 15.72, p < .001). Seventeen per cent of the variation in overall financial burden was explained 
by the following set of independent variables (R² = .18; adjusted R² = .17): number of chronic conditions (standardised 
coefficient, β = .29, p < .001), ethnic background (β = .19, p < .001), age (β = -.18, p < .001), presence of private 
health insurance (β = .16, p < .001), the presence of an unpaid carer (β = .15, p < .001), and educational background 
(β = .09, p < .05). 
 
4. Discussion 
Despite recent popularity, the description and measurement of treatment burden is an area in need of substantial 
development and research. This is the first study to attempt to describe overall treatment burden in a large sample of 
Australians with multiple chronic conditions. There is little data against which we can compare the mean global 
treatment burden in our sample. In developing this instrument, Tran et al. [1] divided their sample into three clusters 
with mean global scores of low = 11.3 (SD = 9.2), moderate = 34.6 (SD = 11.1) and high = 65.8 (SD 18.1) out of 130; 
these clusters were defined as low, moderate and high treatment burden respectively. Although their sample was not 
comparable to ours as over half were hospital inpatients, our community sample reported at least a moderate level of 
treatment burden (mean = 56.5, SD = 34.5 out of 150) using these cut-off points. However, what was notable in our 
sample was the substantially greater variation in burden than found in the original hospitalised sample used by Tran 
et al. [1] suggesting a more heterogeneous experience following discharge, as would be expected. Our study has 
indicated that a substantial proportion of community-dwelling adults with chronic conditions have considerable levels 
of treatment burden. Importantly, these levels of burden may be amenable to prevention through the provision of 
adequate support and/or different professional practices. The impact of these high levels of treatment burden remains 
unknown and often undetected. 
As expected, treatment burden increased with an increasing number of chronic conditions. However, treatment 
burden also decreased with increasing age, which appeared counter-intuitive, given that illness and medication use 
increases with age. Age was also a significant predictor of all domains of treatment burden. For example, age showed 
significant relationships (in terms of size and statistically) with income (-.27, p < 0.001), reaching the Pharmaceutical 
Benefits Scheme (PBS) Safety Net (.33, p < .001), number of co-morbidities (.27, p < .001), cardiovascular conditions 
(.46, p < .001), and musculoskeletal conditions (.28, p < .001). This may be explained in the context of the significant 
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relationship between age and employment. For instance, younger individuals are more likely to be in employment, 
and therefore, in the Australian health system, less likely to have a concession card that reduces the co-payment cost 
associated with obtaining medicines and other treatments. Indeed, existing research suggests that some participants 
prioritise their medications according to cost and their capacity to pay, and at times, decide not to purchase medications 
that are not covered by pharmaceutical concession [6]. However, this effect may also be associated with the fact that 
burden of this kind is more socially sanctioned in older people and may be perceived as having greater impact on 
lifestyle for younger people. Alternatively, it may suggest that people become accustomed to what they have to do 
and see it as less burdensome or have more time when they retire. Clearly, the reasons why younger age was associated 
with increased burden is worthy of further research.  
Although having more chronic conditions predicted increased treatment burden, a self-reported presence of 
diabetes or another endocrine condition was associated with a substantial increase beyond that associated with number 
of conditions. The presence of diabetes, which is a growing chronic condition in developed nations, was associated 
with an increase in treatment burden three times that observed in other conditions and appeared to be particularly 
relevant to social, medical and administrative burden rather than lifestyle and financial burden. Previous research has 
identified the extensive treatment burden in patients with diabetes associated with continual monitoring, medication 
administration, access to services and treatment side-effects [19]. Importantly, this finding confirms that simplifying 
the management of diabetes represents an opportunity to minimise treatment burden. The only dimension of treatment 
burden not impacted by diabetes was financial burden, perhaps reflecting the assistance that is available through the 
national diabetes program in Australia.  
Having an unpaid carer predicted a substantial increase in treatment burden. However, it is possible that when 
health deteriorates to the point that one’s relatives or friends are imposed upon to provide care, one’s sense of burden 
increases as a result of guilt and shame. Interestingly, treatment burden was not associated with being both a consumer 
and a carer, suggesting that being forced to receive care may be perceived as a greater source of treatment burden than 
having to provide care. We believe this may reflect the possible psychological states of some carers and carer-
recipients. For example, carer-recipients may experience feelings of guilt and shame for burdening a family member 
to care for them while carers may feel a sense of self-worth and satisfaction for caring for a loved one. 
When the five components of treatment burden were examined separately, social, medicine and administrative 
burden were predicted by the same cluster of variables (i.e., number of conditions, presence of an unpaid carer, age 
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and presence of diabetes). This finding suggests that these elements of burden are highly inter-related and could be 
addressed through the same changes in practice. However, unlike these dimensions of burden, lifestyle and financial 
dimensions of burden were predicted by education level. Thus, lifestyle and financial burden appeared to be 
experienced more by people with higher levels of education. This finding could reflect the possibility that those with 
higher levels of education were engaged in activities that were significantly disrupted by treatment activities (e.g., 
employment, studying). Financial burden was predicted by a number of additional variables, namely; ethnicity and 
health insurance. Those who had private health insurance and those from a non-Caucasian background experienced 
higher levels of financial burden. Increasing rates of premiums individuals must pay to maintain private health 
insurance and the low levels of English literacy among non-Caucasian backgrounds (who may be less able to navigate 
the health care system or understand their treatment) may offer a possible explanation for these findings. 
Strengths of this study include the use of face-to-face interviews to involve those unable to use the telephone or 
who preferred this interaction, and the large and diverse sample, with a strong representation from Aboriginal or Torres 
Strait Islander Australians and ethnic minority groups. To our knowledge this is the first study that has combined the 
analysis of patient treatment burden with that of unpaid carers. Including unpaid carers to the study sample represents 
a significant contribution to the literature on treatment burden because unpaid carers may be managing their own 
illnesses, in addition to doing the "work" of alleviating a family member's treatment burden. Whilst there were some 
differences in the characteristic of our sample and this of the general Australian population who report chronic 
condition(s), this does not limit our analyses, which sought to identify predictors of treatment burden in those with 
chronic condition(s). Further, whilst this survey was undertaken in an Australian population, it would be reasonable 
to consider that the predictors of treatment burden might be similar in other high-income countries where the health 
system is similar, such as the United Kingdom, Canada, and some parts of Europe – although this would need 
confirmation with further studies. Our study aimed to access the opinions of individuals who were regular users of 
pharmacy and healthcare services, as well as those who were not. Thus, the conclusions drawn from our study require 
confirmation in other samples before they can be generalised to the Australian population, or indeed other populations, 
more widely. We also acknowledge the benefits and limitations of self-reported health status and the low possibility 
of our findings being due to chance. Finally, the TBQ©, used to measure treatment burden in this study is relatively 
new and further validation of this instrument in the study sample would have been beneficial before this study took 
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place. Nevertheless, our study makes strong contributions towards conceptualising treatment burden and the 
identification of those for whom this is most problematic. 
 
5. Conclusion 
Although our study has not addressed the question of how we can improve treatment burden, it has identified 
some people who could benefit from targeted strategies aimed at reducing burden. In particular, health professionals 
should be aware that younger adults with multiple chronic conditions, particularly diabetes or endocrine conditions 
and those with an unpaid carer may be at particular risk of treatment burden. In addition, those with health insurance, 
higher levels of education and ethnic backgrounds may be at risk of financial burden. The routine inclusion of 
treatment burden measures in clinical trials has been suggested as an important consideration to improve the evaluation 
of the treatment burden associated with health care interventions and management strategies [20]. Importantly, the 
development and application of appropriate measures in this context would also expand our understanding of this 
under-researched concept and the extent of the problem.  
 
Acknowledgements We thank all participants for completing the survey. We are grateful to Beth Hunter, 
Rhonda Knights, Nicholas Moir, Brittany Williams and community leaders who supported us in recruiting 
participants. We thank Gabor Mihala for assistance with data management and Jean Spinks for support with data 
analysis. 
 
Author’s contributions AS drafted the manuscript. AW, MK, JW, FK, and EK participated in the design of the 
main study. SM, AS, MK, AW, EK, and FK were involved in designing and facilitating the surveys. AS, SM and 
FK analysed the data. All authors read and approved the final manuscript. 
 
Compliance with Ethical Standards 
Funding This project was funded by the Australian Government Department of Health as part of the Fifth 
Community Pharmacy Agreement Research and Development Programme managed by The Pharmacy Guild of 
Australia. The financial assistance provided must not be taken as endorsement of the contents of this study. 
 
Treatment burden and chronic illness 
 
17 
Competing interests AS, JAW, SM, EK, FK, MAK, and AJW declare that they have no competing interests. 
 
Ethical approval  Approval for this study was obtained from a University Human Ethics Committee 
(PHM/12/11/HREC), and from one state Government Health Department. Informed consent was obtained from all 
individuals who participated in the study. Thus study was conducted in accordance with the World Medical 
Association’s (WMA) Declaration of Helsinki. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
1. Tran V-T, Montori VM, Eton DT, Baruch D, Falissard B, Rvaud P. Development and description of measurement 
properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC 
Medicine. 2012;10(68):1-10.  
2. Mair FS, May CR. Thinking about the burden of treatment. British Medical Journal. 2014;349:1-2. 
3. Gallacher K, Morrison D, Jani B, Macdonald S, May CR, Montori VM, et al. Uncovering Treatment Burden as a 
Key Concept for Stroke Care: A Systematic Review of Qualitative Research. PLoS Medicine. 2013;10:1-17.  
4. Tran V-T, Barnes C, Montori V, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country 
web-based qualitative study of patients with chronic conditions. BMC Medicine. 2015;131:115.  
Treatment burden and chronic illness 
 
18 
5. Demain S, Gonçalves A-C, Areia C, Oliveira R, Marcos AJ, Marques A, et al. Living with, managing and 
minimising treatment burden in long term conditions: A systematic review of qualitative research. PLoS One. 
2015;1:e0125457.  
6. Sav A, Kendall E, McMillan SS, Kelly F, Whitty JA, King MA, et al. ‘You say treatment, I say hard work’: 
treatment burden among people with chronic illness and their carers in Australia. Health & Social Care in the 
Community. 2013;21:665-74.  
7. Moss L, Crane PB. Exploring polypharmacy in elderly women after myocardial infarction. Journal of Women and 
Aging. 2010;22:22-33.  
8. Eton DT, Oliveira OR, Egginton JS, Odell L, May CR, Montori VM. Building a measurement framework of 
burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Related Outcome 
Measures. 2012;3:39-49.  
9. May C, Montori VM, Mair FS. We need minimally disruptive medicine. British Medical Journal. 2009;339:485-
87.  
10. Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F, et al. Burden of treatment for chronic illness: a 
concept analysis and review of the literature. Health Expectations. 2015;18:312-24.  
11. Sav A, McMillan SS, Kelly F, Kendall E, Whitty JA, King MA, et al. Treatment burden among people with 
chronic illness: what are consumer health organizations saying? Chronic Illness. 2013;9:220-32. 
12. Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, et al. A systematic review of patient-
reported measures of burden of treatment in three chronic diseases. Patient Related Outcome Measures. 2013;4:7-20.  
13. Hyland M, Whalley B, Jones R, Masoli M. A qualitative study of the impact of severe asthma and its treatment 
showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res. 2015;24:631-9.  
14. Caughey G, Vitry A, Gilbert A, Roughead E. Prevalence of comorbidity of chronic diseases in Australia. BMC 
Public Health. 2008;8:221.  
15. Australian Institute of Health and Welfare. Australian Burden of Disease Study: fatal burden of disease 2010. 
Canberra: Australian Institute of Health and Welfare;2015. 
16. Whitty JA, Kendall E, Sav A, Kelly F, McMillan SS, King MA, et al. Preferences for the delivery of community 
pharmacy services to help manage chronic conditions. Research in Social and Administrative Pharmacy. 
2015;11:197-215. 
17. Tran V-T, Harrington M, Montori V, Barnes C, Wicks P, Ravaud P. Adaptation and validation of the Treatment 
Burden Questionnaire (TBQ) in English using an internet platform. BMC Medicine. 2014;12:109.  
18. Australian Bureau of Statistics. National Health Survey 2007-2008. Canberra: Australian Bureau of 
Statistics; 2013. 
19. Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed Patients: A videographic analysis of 
how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters. 
Diabetes Care. 2012;35:47-9. 
20. Bernhard J, Maibach R, Thurlimann B, Sessa C, Aapro MS. Patients' estimation of overall treatment burden: 
why not ask the obvious? Journal of Clinical Oncology. 2002;20:65-72.  
